PERRIGO Co plc (PRGO) stock
PRGONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3029% below fair value
$16.24+0.06 (+0.37%)
Close on Nov 13, 2026Market cap $2.25BP/E –Yield 7.14%
Perrigo total assets
Total assets on the balance sheet at the end of each period.
Perrigo's total assets was $7.48B at Sep 26, 2026. For fiscal 2025 it was $8.54B, down 11.5% from the year before. Over ten years it grew -4.7% a year on average. The highest annual figure on record is $19.59B in fiscal 2015.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.54B | -11.5% |
| FY2024 | Dec 31, 2024 | $9.65B | -10.7% |
| FY2023 | Dec 31, 2023 | $10.81B | -1.9% |
| FY2022 | Dec 31, 2022 | $11.02B | +5.7% |
| FY2021 | Dec 31, 2021 | $10.43B | -9.3% |
| FY2020 | Dec 31, 2020 | $11.49B | +1.7% |
| FY2019 | Dec 31, 2019 | $11.30B | +2.9% |
| FY2018 | Dec 31, 2018 | $10.98B | -5.6% |
| FY2017 | Dec 31, 2017 | $11.63B | -40.6% |
| FY2015 | Jun 27, 2015 | $19.59B | +41.2% |
| FY2014 | Jun 28, 2014 | $13.88B | +160.1% |
| FY2013 | Jun 29, 2013 | $5.34B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 26, 2026 | $7.48B | -25.8% |
| Q2 FY2026CQ2 2026 | Jun 27, 2026 | $7.61B | -24.6% |
| Q1 FY2026CQ1 2026 | Mar 28, 2026 | $7.98B | -18.2% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $8.54B | -11.5% |
| Q3 FY2025CQ3 2025 | Sep 27, 2025 | $10.08B | -10.0% |
| Q2 FY2025CQ2 2025 | Jun 28, 2025 | $10.09B | -2.9% |
| Q1 FY2025CQ1 2025 | Mar 29, 2025 | $9.76B | -8.3% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $9.65B | -10.7% |
| Q3 FY2024CQ3 2024 | Sep 28, 2024 | $11.20B | +4.1% |
| Q2 FY2024CQ2 2024 | Jun 29, 2024 | $10.40B | -5.2% |
| Q1 FY2024CQ1 2024 | Mar 30, 2024 | $10.64B | -2.9% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $10.81B | -1.9% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $10.76B | +0.8% |
| Q2 FY2023CQ2 2023 | Jul 1, 2023 | $10.96B | +0.4% |
| Q1 FY2023CQ1 2023 | Apr 1, 2023 | $10.95B | +5.4% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $11.02B | +5.7% |
| Q3 FY2022CQ3 2022 | Oct 1, 2022 | $10.68B | -2.2% |
| Q2 FY2022CQ2 2022 | Jul 2, 2022 | $10.92B | -2.8% |
| Q1 FY2022CQ1 2022 | Apr 2, 2022 | $10.39B | -8.3% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $10.43B | -9.3% |
| Q3 FY2021CQ3 2021 | Oct 2, 2021 | $10.92B | -5.7% |
| Q2 FY2021CQ2 2021 | Jul 3, 2021 | $11.23B | -7.4% |
| Q1 FY2021CQ1 2021 | Apr 3, 2021 | $11.32B | -0.7% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $11.49B | +1.7% |
| Q3 FY2020CQ3 2020 | Sep 26, 2020 | $11.58B | +2.3% |
| Q2 FY2020CQ2 2020 | Jun 27, 2020 | $12.13B | +6.1% |
| Q1 FY2020CQ1 2020 | Mar 28, 2020 | $11.40B | +2.5% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $11.30B | +2.9% |
| Q3 FY2019CQ3 2019 | Sep 28, 2019 | $11.31B | +3.4% |
| Q2 FY2019CQ2 2019 | Jun 29, 2019 | $11.43B | +1.8% |
| Q1 FY2019CQ1 2019 | Mar 30, 2019 | $11.12B | -4.5% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $10.98B | -5.6% |
| Q3 FY2018CQ3 2018 | Sep 29, 2018 | $10.94B | -7.6% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $11.23B | -4.8% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $11.64B | -16.7% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $11.63B | -40.6% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $11.84B | – |
| Q2 FY2017CQ2 2017 | Jul 1, 2017 | $11.79B | – |
| Q1 FY2017CQ1 2017 | Apr 1, 2017 | $13.98B | – |
| Q4 FY2015CQ2 2015 | Jun 27, 2015 | $19.59B | – |
See a number that looks wrong?